BPM31510 not checked

BPGbio · API 31510

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.”In the company’s words, NCT04752813 on ClinicalTrials.gov
Tested for
Glioblastoma, Glioblastoma Multiforme
Main trialPhase 2
“This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.”In the company’s words, NCT04752813 on ClinicalTrials.gov
Other names
API 31510 · Ubidecarenone · USP

Other drugs for Glioblastoma

All 94 drugs for Glioblastoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 25 Aug 2026 A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Phase 2Completed 11 Jun 2019 BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
Phase 1/2Completed Jan 2010 Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BPM31510

Following is part of Solo: you see every change to BPM31510 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in